Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508577 | 0.86 | CYP17A1 (0.42) | EPHX2PDE2AHCRTR1HCRTR2P2RX7 | |
| SCHEMBL8926703 | 0.86 | EPHX2 (0.44) | EPHX2PDE2AHCRTR1HCRTR2P2RX7 | |
| SCHEMBL4444828 | 0.85 | KCNN4 (0.41) | EPHX2 | |
| SCHEMBL2239066 | 0.85 | RXRA (0.37) | EPHX2HCRTR1HCRTR2P2RX7 | |
| SCHEMBL7769695 | 0.84 | KDM4E (0.35) | EPHX2 | |
| SCHEMBL25182236 | 0.81 | EPHX2 (0.50) | EPHX2PDE2AHCRTR1HCRTR2P2RX7 | |
| SCHEMBL2245517 | 0.81 | MBOAT4 (0.43) | EPHX2 | |
| SCHEMBL2447332 | 0.81 | EPHX2 (0.50) | EPHX2PDE2AHCRTR1HCRTR2P2RX7 | |
| SCHEMBL6468220 | 0.81 | PDE2A (0.46) | EPHX2PDE2AHCRTR1HCRTR2P2RX7 | |
| SCHEMBL19888008 | 0.81 | EPHX2 (0.46) | EPHX2PDE2AHCRTR1HCRTR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| EP-3455224-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-20230052528-A1 | TASPASE1 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-02-16 | — | — | US | disclosed |
| CN-115697331-A | TASPASE1 inhibitors and uses thereof | 加利福尼亚大学董事会 | 2023-02-03 | — | — | CN | disclosed |
| EP-4065112-A2 | TASPASE1 INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-109476658-B | Substituted 5,6,7, 8-tetrahydro [1,2,4] triazolo [4,3-a ] pyridin-3 (2H) -ones and 2,5,6, 7-tetrahydro-3H-pyrrolo [2,1-c ] [1,2,4] triazol-3-ones and uses thereof | 拜耳公司 | 2021-08-10 | — | — | CN | disclosed |
| WO-2021102359-A2 | TASPASE1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| US-10722501-B2 | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-28 | — | — | US | disclosed |
| CN-107074822-B | Triazole compounds as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-03-12 | — | — | US | disclosed |
| EP-2820005-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-01-07 | — | — | EP | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| WO-2013128378-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2013-09-06 | — | — | WO | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012049555-A1 | SPIROCYCLIC COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2012-04-19 | — | — | WO | disclosed |
| US-20040152903-A1 | 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides | KUREHA CORPORATION (JP) | 2004-08-05 | — | — | US | disclosed |
| EP-1375483-A1 | 6-CHLORO-3-PYRIDYLMETHYLPROPYLAMINE DERIVATIVES, PREPARATION PROCESS THEREOF AND BACTERICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | GPR55, GPR65, GPR35 | EPHX2 1152/4885PDE2A 2247/4885HCRTR1 567/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | EPHX2 3244/4885PDE2A 2296/4885HCRTR1 2/4885 |
| US-20040152903-A1 | 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides | PGLS, TLR6, UROD | EPHX2 1579/4885PDE2A 1783/4885HCRTR1 4319/4885 |
| US-10722501-B2 | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof | PTGIS, CYP11B2, IL1B | EPHX2 851/4885PDE2A 503/4885HCRTR1 3609/4885 |
| US-20230052528-A1 | TASPASE1 INHIBITORS AND USES THEREOF | RNASE1, TASP1, TPP1 | EPHX2 3278/4885PDE2A 3022/4885HCRTR1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.